RxDoctor Payments DataLook up a doctor →

Hayden Long, MD

Neurology · Mobile, ALNPI 1700093598

Payments from drug & device makers

$386,169in general payments, 2019–2025

Across 1,971 payments — averaging $195.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$235K
  • Biohaven Pharmaceuticals, Inc.$74K
  • Biohaven Pharmaceutical Holding Company Ltd.$53K
  • UCB, Inc.$7K
  • SK Life Science, Inc.$2K
  • AstraZeneca$2K
  • plus $14K from 48 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)598$235,028
Biohaven Pharmaceuticals, Inc.168$74,032
Biohaven Pharmaceutical Holding Company Ltd.117$52,822
UCB, Inc.171$7,180
SK Life Science, Inc.79$1,926
AstraZeneca78$1,547
Lundbeck LLC53$1,089
Amgen57$1,072
Acadia Pharmaceuticals Inc66$1,049
Pfizer73$903
Lilly USA, LLC57$887
Eisai Inc.42$837
Teva Pharmaceuticals USA, Inc.39$813
Supernus Pharmaceuticals, Inc.70$760
Novartis34$671
Nevro Corp.17$609
Argenx US, Inc.23$599
MDD US Operations, LLC11$468
Biogen29$465
Neurelis, Inc.18$449
EMD Serono, Inc.24$353
Arbor Pharmaceuticals, Inc.19$258
Johnson & Johnson(2 entities)10$226
Otsuka America Pharmaceutical, Inc.11$208
CSL Behring6$164
Currax Pharmaceuticals LLC11$157
Idorsia Pharmaceuticals US Inc10$156
Livanova USA, Inc.6$116
Impel Pharmaceuticals Inc.8$111
Tanabe Pharma America, Inc.5$109
Sanofi6$100
Jazz Pharmaceuticals Inc.4$95
Endo Pharmaceuticals Inc.5$93
Zyla Life Sciences, Inc.5$74
GE HealthCare4$73
Acorda Therapeutics, Inc5$67
Takeda Pharmaceuticals U.S.A., Inc.3$62
Grifols USA, LLC3$60
Sumitomo Pharma America, Inc.3$55
Upsher-smith Laboratories LLC3$49
Catalyst Pharmaceuticals, Inc.2$43
Boston Scientific2$43
Neurocrine Biosciences, Inc.3$41
Avanir Pharmaceuticals, Inc.2$33
Mallinckrodt Enterprises LLC2$33
Alnylam Pharmaceuticals Inc.1$28
Abbott1$25
Life Molecular Imaging Ltd1$22
Azurity Pharmaceuticals, Inc.1$21
Kedrion Biopharma, Inc.1$20
Neuronetics, Inc.1$19
Sonex Health, Inc.1$19
Shire North American Group Inc1$17
Amylyx Pharmaceuticals, Inc.1$14

How this compares

$386,169 in reported general payments places this provider in the 90th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama →

Medicare billing

Part B allowed, 2024
$320,932
Medicare patients
486
Services billed
4,755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Mobile

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →